{"id":"W4321795635","doi":"10.1177/17588359231152843","title":"Quality of life with ribociclib <i>versus</i> abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Novartis (Canada)","funders":"National Cancer Institute; Eli Lilly and Company; Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Medicine; Breast cancer; Internal medicine; Quality of life (healthcare); Oncology; Placebo; Cancer; Hazard ratio; Clinical trial; Confidence interval; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004558647,0.00131513,0.003693532,0.0008582408,0.0001945566,0.001011486,0.001000503,0.001034181,0.006479251],"category_scores_gemma":[0.006086348,0.0004176467,0.007158555,0.0006510135,0.0005622237,0.0008331168,0.001007191,0.00173484,0.0003810218],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001282238,"about_ca_system_score_gemma":0.0008634902,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00160458,"about_ca_topic_score_gemma":0.002132027,"domain_scores_codex":[0.9949857,0.003473969,0.0004948797,0.0003729835,0.0004059461,0.0002665992],"domain_scores_gemma":[0.9962785,0.00193383,0.001120462,0.0002177556,0.0001846371,0.0002648573],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.9408383,0.001401455,0.004341665,0.003162768,0.02405036,0.00003385864,0.00007764095,0.001909557,0.0007301212,0.0004546657,0.000738028,0.02226164],"study_design_scores_gemma":[0.571004,0.2718502,0.06043581,0.001072023,0.07263499,0.0001874819,0.000253453,0.01164693,0.002402539,0.002740616,0.00561789,0.0001541074],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.972611,0.01393412,0.001472269,0.0003589603,0.0005541122,0.002556158,0.003695462,0.00006753881,0.004750501],"genre_scores_gemma":[0.9926583,0.001485696,0.001110336,0.0002423741,0.0001209364,0.002072775,0.00114509,0.00001039431,0.001154168],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006479251,"threshold_uncertainty_score":0.02410877,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06506842105089145,"score_gpt":0.4343277424711693,"score_spread":0.3692593214202778,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}